Blood biomarker may spot early IPF
NCT ID NCT03457935
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a molecule called miR200 in the blood can help detect idiopathic pulmonary fibrosis (IPF), a lung-scarring disease, at an early stage. Researchers will compare miR200 levels in 450 people: those with IPF, those with other lung diseases, and healthy volunteers. The goal is to find a simple blood test for earlier diagnosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Temple University
Philadelphia, Pennsylvania, 19140, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill slow lung scarring in IPF?
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can umbilical cord stem cells ease a scarring lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- A smarter way to track lung disease? new platform aims to personalize COPD and IPF care